Pasithea Total Current Liabilities vs Selling General Administrative Analysis
| KTTA Stock | USD 3.10 0.08 2.52% |
Pasithea Therapeutics financial indicator trend analysis is much more than just breaking down Pasithea Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pasithea Therapeutics is a good investment. Please check the relationship between Pasithea Therapeutics Total Current Liabilities and its Selling General Administrative accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pasithea Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Total Current Liabilities vs Selling General Administrative
Total Current Liabilities vs Selling General Administrative Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pasithea Therapeutics Total Current Liabilities account and Selling General Administrative. At this time, the significance of the direction appears to have strong relationship.
The correlation between Pasithea Therapeutics' Total Current Liabilities and Selling General Administrative is 0.76. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Selling General Administrative in the same time period over historical financial statements of Pasithea Therapeutics Corp, assuming nothing else is changed. The correlation between historical values of Pasithea Therapeutics' Total Current Liabilities and Selling General Administrative is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Pasithea Therapeutics Corp are associated (or correlated) with its Selling General Administrative. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Selling General Administrative has no effect on the direction of Total Current Liabilities i.e., Pasithea Therapeutics' Total Current Liabilities and Selling General Administrative go up and down completely randomly.
Correlation Coefficient | 0.76 |
| Relationship Direction | Positive |
| Relationship Strength | Significant |
Total Current Liabilities
Total Current Liabilities is an item on Pasithea Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Pasithea Therapeutics Corp are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Selling General Administrative
Most indicators from Pasithea Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pasithea Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pasithea Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. At present, Pasithea Therapeutics' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Issuance Of Capital Stock is expected to grow to about 31 M, whereas Sales General And Administrative To Revenue is forecasted to decline to 16.32.
| 2010 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 1.4K | 32.4K | 517.7K | 543.5K | Cost Of Revenue | 17.3K | 113.2K | 648.5K | 680.9K |
Pasithea Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Pasithea Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Pasithea Therapeutics is a strong investment it is important to analyze Pasithea Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pasithea Therapeutics' future performance. For an informed investment choice regarding Pasithea Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pasithea Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pasithea Therapeutics. If investors know Pasithea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pasithea Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (14.79) | Revenue Per Share 0.37 | Quarterly Revenue Growth 14.981 | Return On Assets (0.38) | Return On Equity (0.63) |
The market value of Pasithea Therapeutics is measured differently than its book value, which is the value of Pasithea that is recorded on the company's balance sheet. Investors also form their own opinion of Pasithea Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Pasithea Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pasithea Therapeutics' market value can be influenced by many factors that don't directly affect Pasithea Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pasithea Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pasithea Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pasithea Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.